AP Pharma makes new appointment
This article was originally published in Scrip
The US speciality pharmaceutical company AP Pharma has named John Whelan vice-president of finance and chief financial officer. He succeeds Gregory Turnbull, who was serving as interim chief financial officer and will remain a company director and a member of the board's executive committee. Mr Whelan was previously chief operating officer and chief financial officer at Raven biotechnologies.
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.